John Giacona, PhD, PA-C

great HTN JC discussion today on BAXHTN study by Dr. Shawna Nesbitt joined by @dramitkhera.bsky.social @giaconajohn.bsky.social @utswim.bsky.social Interesting that baseline aldosterone in the trial was around 7.5 ng/dL by LCMS with baseline PRA is 1 ng/mlhr. This means that majority of pts have PA

🏆 First time at Epic Cosmos Datathon—our team took 1st place! Grateful for the collaboration and hands on experience ! @drwanpen.bsky.social Excited to present tomorrow (Oct 3) at Pegasus Park Symposium on “Missed Opportunities: Screening for Primary Aldosteronism” #EpicCosmos #HTN

Excellent commmentary from @giaconajohn.bsky.social and @drwanpen.bsky.social

Optimal Treatment of Primary Aldosteronism: Can We Compare Apples to Oranges? Primary aldosteronism (PA) is an endocrine disorder characterized by inappropriate and excessive aldosterone production.1 PA is a prevalent cause of elevat

Comparing Management strategies for Primary Aldosteronism: Is it 🍎 versus 🍊 ?

Commentary academic.oup.com/ajh/article-...

based on
academic.oup.com/ajh/article-...

#Hypertension #Aldosteronism

Subclinical primary aldosteronism is an under-recognized driver of cardiovascular risk. Could it be a new target for CV prevention? Read our Circulation editorial —>

Our new study that links high Phosphate diet found in processed food and anxiety behavior and alternation of genes involved in mood regulation in mice. That may explain why we don't feel good after a whopper or a big Mac @hkkimphd.bsky.social @utswim.bsky.social sciencedirect.com/science/arti...

great HTN journal club discussing GWAS in primary aldosteronism by @jdmosley-moses.bsky.social @giaconajohn.bsky.social www.ahajournals.org/doi/10.1161/...

So much fun AHA #Hypertension25 gala dinner learning history of HTN from Bill Cushman and visiting with friends @anastasiasmihaili.bsky.social @giaconajohn.bsky.social @spjuraschek.bsky.social

Thank you, Dr. Yuan , and the program committee @drwanpen.bsky.social , and @tammybrady.bsky.social for the opportunity to discuss this important topic!

@giaconajohn.bsky.social excellent talk highlights that intensive lowering of BP leads to lower not higher risk of OH based on metaanalysis of RCT by @spjuraschek.bsky.social #Hypertension25 Rx should be titrated to seated BP in OH as per 2025 high BP guidelines

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled #Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial ca. 2025 from @asnpublications.bsky.social @escardio.bsky.social
#Nephpearls #NephSky #ESCCongress

👉 journals.lww.com/jasn/fulltex...

Great dinner celebrating #Hypertension25 together near harbor with UTSW group Angie Price @giaconajohn.bsky.social @robynwei.bsky.social @jesslin23.bsky.social and Mu Huang

Dr Karol Watson starts with impactful message top 10 take away message #Hypertension25 high BP as predictor dementia and treatment reduces cognitive decline or dementia by 15% . Once you hit 120/80 , trajectory to high BP is steep. Don’t sit on high BP! @ahascience.bsky.social

Ideal BP < 120/80 mmHg! #Hypertension25

Congratulations @robynwei.bsky.social RD/ PhD candidate for her poster #Hypertension25 highlighting underutilization of salt substitute use in the US @giaconajohn.bsky.social details in AHA News release newsroom.heart.org/news/u-s-sur... @ahascience.bsky.social

U.S. survey finds salt substitutes rarely used by people with high blood pressure Research Highlights: Despite their effectiveness in lowering sodium intake and managing blood pressure, salt substitutes were rarely used by people with high blood pressure, according to a review of a...

Honored to present my abstract poster at the AHA #hypertension25 on the prevalence of salt substitute use. Grateful that our work @drwanpen.bsky.social @giaconajohn.bsky.social
@jesslin23.bsky.social was also featured in the official AHA news release: newsroom.heart.org/news/u-s-sur...

Kicked off the day with a run around Baltimore Harbor 🌊🏃‍♂️ at #Hypertension25. A reminder that movement matters — let’s keep championing lifestyle and physical activity as powerful tools to reduce CVD and BP! @ahascience.bsky.social

Outstanding review of resistant hypertension at #HTN25 by Drs. @drwanpen.bsky.social , Keith Ferdinand, and Ty Gluckman — from current challenges in care to exciting new agents in the pipeline. Great insights into where the field is heading!

Thank you to AHA for the opportunity to present at AHA HTN scientific session 25 in Baltimore. Having an amazing time meeting and connecting with experts in the field! @drwanpen.bsky.social @giaconajohn.bsky.social
@robynwei.bsky.social

Great talk #Hypertension25 by @jesslin23.bsky.social in discussing limitations of visual estimation of home BP in clinical decision in Rx HTN in Eyeball study @robynwei.bsky.social @giaconajohn.bsky.social

Fantastic opening session at AHA #HTN25 — great energy, insights, and inspiration already flowing. Excited for the great science and rich discussions ahead! @ahascience.bsky.social @drwanpen.bsky.social

Got to Baltimore #Hypertension25 so excited to see friends and colleagues talking about high BP ! @ahascience.bsky.social @giaconajohn.bsky.social

❓What’s new in BP care?
🎥 Watch the #TargetBP webinar on the 2025 @AHAScience / @ACCinTouch Hypertension Guidelines w/ @drwanpen.bsky.social , @jordybc.bsky.social , Keith Ferdinand, & Dan Jones 👉 targetbp.org

Join us @jordybc.bsky.social , Keith Ferdinand, and Dan Jones unpacking 2025 AHA/ACC guidelines on Thursday Aug 28 bit.ly/Guideline25W... @UTSWInternalMed @utswheart

New 2025 AHA/ACC Hypertension Guidelines are out! You will not want to miss this webinar! Sign up 👇

Another great HTN JC by @giaconajohn.bsky.social on AVIM therapy, which just received BDD status. A niche pacemaker for pt with systolic HTN but concerns remain for reduced cardiac output from AV dyssynchrony+ chronic RV pacing. with this high BP variability, how can oscillometric BP be accurate?

Our latest clinical practice guideline, Primary Aldosteronism (bit.ly/44MbrSv), is now available. The new guideline recommends more widespread screening for a common hormonal cause of high blood pressure known as primary aldosteronism. Read in @endocrinenews.bsky.social: bit.ly/4kFadhv #ENDO2025

Efficacy and Side-Effect Profile of Baxdrostat in Patients with Primary Aldosteronism.

A medical adrenalectomy?

ASIs advance - Baxdrostat in primary aldosteronism now www.nejm.org/doi/full/10.... n = 15 single arm trial from @adinaturcu.bsky.social and @astra-zeneca.bsky.social in @nejm.org

~ 25/10 mm Hg BP lowering and impressive aldosterone level drop

#Hypertension #EndoSky

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline AbstractBackground. Primary aldosteronism (PA), a primary adrenal disorder leading to excessive aldosterone production by one or both adrenal glands, is a

New PA Endo guideline is also out by experts @anandvaidya17.bsky.social #Cardiosky @hswapnil.medsky.social doi.org/10.1210/clin...

A figure showing the changes from baseline in systolic blood pressure (SBP), plasma aldosterone–renin ratio (ARR), and serum potassium level for each patient.

In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia. Full SPARK study results: nej.md/40Js1kz

#ENDO2025